Cholestasis-induced fibrosis is reduced by interferon α-2a and is associated with elevated liver metalloprotease activity
- 1 December 2000
- journal article
- Published by Elsevier in Journal of Hepatology
- Vol. 33 (6) , 915-925
- https://doi.org/10.1016/s0168-8278(00)80123-3
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Histological outcome in interferon alpha-2b treated patients with chronic posttransfusion non-A, non-B hepatitisLiver International, 2008
- Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic viewGastroenterology, 1999
- The Significance of Colocalization of Plasminogen Activator Inhibitor-1 and Vitronectin in Hepatic FibrosisScandinavian Journal of Gastroenterology, 1997
- Transcriptional Control of Matrix Metalloproteinases and the Tissue Inhibitors of Matrix MetalloproteinasesCritical Reviews™ in Eukaryotic Gene Expression, 1997
- Interf eron-α2b Increases Fibrolysis in Fibrotic Livers from Bile Duct Ligated Rats: Possible Participation of the Plasminogen ActivatorPharmacology, 1995
- Randomised trial of lymphoblastoid α-interferon in chronic hepatitis C: Effects on inflammation, fibrogenesis and viremiaJournal of Hepatology, 1993
- Extracellular Matrix DegradationPublished by Springer Nature ,1991
- Recombinant Interferon Alfa Therapy for Chronic Hepatitis CNew England Journal of Medicine, 1989
- Evaluation of colchicine therapy in primary biliary cirrhosisGastroenterology, 1988
- Double blind controlled trial of d-penicillamine in patients with primary biliary cirrhosis.Gut, 1985